Children’s Health Defense demanded that the Food and Drug Administration (FDA) withdraw its approval of the antiviral drug remdesivir for children.
Dr. Madhava Setty, senior science editor for CHD’s Defender newsletter, cited 72 percent of children hospitalized with COVID-19 who “suffered adverse events” as a reason why remdesivir should not be approved.
Children’s Health Defense demands FDA withdraw its approval of Remdesivir for infants and children, citing 72% adverse events rate https://t.co/ukD524ruHU
— ꧁✬Ｈυ𝓵ᵃ𝔥卂ᶰ𝓭ѕ✬꧂ (@ThehulaG) May 4, 2022
The Defender noted from the clinical study results:
According to the press release, the FDA’s decision to approve the therapy, marketed under the name Veklury, is supported by a clinical study conducted on infants 4 weeks and older weighing a minimum of 6.6 pounds.
The study is underway and will not be completed